• SPX
  • 6032.38
  • 0.56 %
  • 33.6397
  • DJI
  • 44910.65
  • 0.42 %
  • 188.5898
  • N225
  • 38513.02
  • 0.8 %
  • 304.9883
  • FTSE
  • 8277.18
  • -0.12 %
  • -10.12
  • IXIC
  • 19218.166
  • 0.83 %
  • 157.6895
Vaxxinity, Inc. (VAXX) Stock Price, News & Analysis

Vaxxinity, Inc. (VAXX) Stock Price, News & Analysis

Currency in USD Disclaimer

$0.0000

-$0

(0%)

Day's range
$0
Day's range
$0
50-day range
$9.9999997E-5
Day's range
$0.09
  • Country: US
  • ISIN: US92244V1044
52 wk range
$0
Day's range
$1.1


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -15.26
  • Piotroski Score 0.00
  • Grade N/A
  • Symbol (VAXX)
  • Company Vaxxinity, Inc.
  • Price $0.00
  • Changes Percentage (0%)
  • Change -$0
  • Day Low $0.00
  • Day High $0.00
  • Year High $1.10

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/29/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.45
  • Trailing P/E Ratio -0.2
  • Forward P/E Ratio -0.2
  • P/E Growth -0.2
  • Net Income $-56,934

Income Statement

Quarterly

Annual

Latest News of VAXX

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Vaxxinity, Inc. Frequently Asked Questions

  • What were the earnings of VAXX in the last quarter?

    In the last quarter Vaxxinity, Inc. earnings were on Wednesday, March, 27th. The Vaxxinity, Inc. maker reported -$0.09 EPS for the quarter, beating analysts' consensus estimates of -$0.13 by $0.04.

  • What is the Vaxxinity, Inc. stock price today?

    Today's price of Vaxxinity, Inc. is $0.00 — it has decreased by 0% in the past 24 hours. Watch Vaxxinity, Inc. stock price performance more closely on the chart.

  • Does Vaxxinity, Inc. release reports?

    Yes, you can track Vaxxinity, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Vaxxinity, Inc. stock forecast?

    Watch the Vaxxinity, Inc. chart and read a more detailed Vaxxinity, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Vaxxinity, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Vaxxinity, Inc. stock ticker.

  • How to buy Vaxxinity, Inc. stocks?

    Like other stocks, VAXX shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Vaxxinity, Inc.'s EBITDA?

    Vaxxinity, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Vaxxinity, Inc.’s financial statements.

  • What is the Vaxxinity, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Vaxxinity, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Vaxxinity, Inc.'s financials relevant news, and technical analysis. Vaxxinity, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Vaxxinity, Inc. stock currently indicates a “sell” signal. For more insights, review Vaxxinity, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.